

Synthesis of 2-sulfanyl-6-methyl-1,4-dihydropyrimidines as a new class of antifilarial agents

B.K. Singh,¹ Mridul Mishra,¹ Nisha Saxena,¹ G. P. Yadav², P. R. Maulik², M. K. Sahoo³, R.L. Gaur,³ P. K. Murthy^{3*} and R.P. Tripathi^{1*}

¹Medicinal and Process Chemistry, ²Molecular and structural Biology and

³Parasitology Divisions, Central Drug Research Institute Lucknow-226001

Correspondence:

Email: ¹RP Tripathi: rpt.cdri@gmail.com; rpt.cdri@yahoo.co.in; rp_tripathi@cdri.res.in

³PK Murthy: drpkmurthy@gamil.com; drpkmurthy@yahoo.com

Fax No: +91 522 2623405/ 262938

ABSTRACT

A series of 2-sulfanyl-6-methyl-1,4-dihydropyrimidines (**8-21**) were synthesized in good yields by alkylation of 5-methyl-6-phenyl-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid ethyl ester (**2-7**) with different alkyl or aralkyl halides in presence of a combination of anhydrous K₂CO₃ and catalytic amount of tetrabutyl ammonium bromide. The title compounds were evaluated for their antifilarial activity against adult parasites of human lymphatic filarial parasite *Brugia malayi* (sub-periodic strain) in vitro and in vivo at various concentrations. One of the compounds (**18**) showed promising antifilarial activity.

Keywords: Dihydropyrimidines; 1,4-dihydropyrimidines; antifilarial; *Brugia malayi*, tetrabutylammonium bromide

1. Introduction

Current global estimates suggest that around 80 countries are endemic for lymphatic filariasis (LF) [1-2]. Of the three parasites causing LF, *Wuchereria bancrofti* accounts for over 90% of the global burden. *Brugia malayi* is limited to Asia, and *Brugia timori* to a few islands in Indonesia. It has been estimated that 1.1 billion people living in areas endemic for this disease are exposed to the risk of infection, and that there are about 120 million cases with either disease or infection (microfilaria carriers)[3]. An estimated population of 22 million is known to be host for circulating microfilariae and the 16 million people suffer from filarial manifestations like elephantiasis of limbs, genitals and hydrocoele. Low priority was given to this disease, although it is responsible for significant morbidity and consequently the World Health Assembly has adopted a resolution on the global elimination of lymphatic filariasis as a public health problem [4-6].

The available control strategies have significant limitations as current drugs are principally microfilaricidal and require annual repeated treatment for a number of years, thus there is still a need for the development of a macrofilaricidal agent or drug combination for the curative treatment or sustained suppression of the microfilariae [7-10]. Drug resistance to ivermectin appears to be another issue of concern, especially in areas where diethylcarbamazine (DEC) can not be given. Besides, research is required on the progression and reversibility of disease manifestations.

A number of molecules from heterocycles are known as good antifilarials [11]. Benzimidazoles [12] and triazines [13,14] have recently been shown to possess very good antifilarial activity. In spite of tremendous medicinal chemistry in dihydropyrimidines [15] and their derivatives only scanty reports exist for their antifilarial activity. In recent years interest dihydropyrimidines are being looked as an important class of molecules since many of them are clinical candidates for different diseases [16-18]. S-DABO (Figure 1) and many other analogues have recently been shown to possess anti HIV activities [19-20]. We have recently shown that dihydropyrimidinones show interesting antiparasitic activities [21] via inhibition of crucial enzymes of parasite biochemistry. Herein we have synthesized 2-sulfanyl-6-methyl-1, 4-dihydropyrimidines and evaluated them for the first time for their antifilarial activity both in vitro and in vivo. The method of synthesis is simple and efficient and does not involve any special apparatus or reagents.

Insert Figure 1

2. Results and Discussion

The starting 1,2,3,4-tetrahydropyrimidine-2-thione derivatives were prepared in excellent yields by our earlier reported protocol [22]. It involves a modified Biginelli three component reaction of aromatic aldehydes, ethyl acetoacetate and thiourea in diethylene glycol at 120 °C. The yields and characterization of these tetrahydropyrimidine thiones were already described. In the proposed reaction ethyl acetoacetate and thiourea were kept constant while aromatic aldehydes were the variant.

The target molecules, 2-sulfanyl-6-methyl-1,4-dihydropyrimidines were synthesized from the respective tetrahydropyrimidine-2-thiones by reaction with an alkyl or aralkyl halides in anhydrous acetone in presence of anhydrous K_2CO_3 and catalytic amount of tetrabutylammonium bromide. (Scheme 1, Table 1). It is important to mention here that this class was earlier synthesized by Atwal et. al. [16] as possible Calcium channel blockers, however, our method of synthesis is far better with respect to environmental consideration, time and yields of the final product. Use of tetrabutylammonium bromide as phase transfer catalyst not only improves the yield of the sulfanyl derivatives but the reaction time is also considerably reduced. The structures of all the products were established on the basis of their spectral data and analyses. In IR spectra of the compounds the carbonyl frequency of the ester moiety was observed at around 1650 cm^{-1} along with other usual characteristic frequencies. All the compounds displayed $[M+H]^+$ corresponding to their molecular formulae. In 1H NMR of the compounds three protons of 6-methyl substituent appeared as singlets at around $\delta 2.45$ along with other protons at their usual chemical shifts. Out of the two possibilities of 1,4- and 3,4-dihydroisomers (**A** and **B**) (Figure 2) only the former prevailed as the characteristic signal H-4 was observed at around $\delta 6.50$ as singlet in all the products. Further, the structure of one of such prototype (compound **12**) is established by X-ray crystallographic data (Figure 2).

Please insert Scheme 1

Please insert Figure 2 and Figure 3

The compounds **8-20** synthesized were evaluated *in vitro* for their macrofilaricidal activity against *Brugia malayi* according to the method of Murthy et al. [23] Micro- and macrofilaricidal activities were evaluated following the methods described by Lammler and Wolf [24], Chatterjee *et al.*[25] and Gaur et al [26].

As evident from Table 2 compounds **8, 10, 11, 12, 14, 15, 18** and **19** resulted in complete loss of motility of adult worms of *B. malayi* at 100 μ M concentrations and they have shown 15.4 % to 68.61 % inhibition in MTT reduction assays while compound **19** did not show any inhibition in MTT reduction assay. Of these, 3 compounds (**10, 15** and **18**) affected both motility (irreversible loss) and MTT reduction (~50% inhibition or more) and compounds **8, 11, 12, 14** and **19** either affected motility with <50% MTT reduction or only motility. Further, the compounds showing MTT reduction to the level of around 50% were screened at lower concentration also. Compound **10** at 50 μ M concentration resulted in complete

loss of motility of filarial worms with no inhibition in MTT reduction assay, while at 25 μ M concentration it showed only sluggish motility of filarial worm and displayed approx 30 % inhibition in MTT reduction assay. Compound **15** on the other hand displayed complete loss of motility in filarial worms at 50 μ M concentration with 19% inhibition in MTT reduction assay. Compounds **17** and **19** were not effective at lower concentrations. The best compound of the series was found to be compound **18** which resulted in complete loss of motility at the two lower concentrations (50 and 25 μ M) screened and good inhibition (around 70%) in MTT reduction assay. DEC and the control vehicle did not display any activity against the microfilaria of *B. malayi*. Although no definite conclusion on SAR can be drawn with this sizable number of compounds yet it is clear that 4-aryl-1,4-dihydropyridines bearing less bulky electron withdrawing substituent at the 4th position of phenyl ring (4-F- phenyl) compound **18** is the best compound of the series.

Please insert Table 2

Only three compounds **10**, **15** and **18** showing potent in vitro antifilarial activity were screened in vivo against *B. malayi* in *M. couchea* model to see the effect of the compounds on parasitological parameters and the results are depicted in Table 3. As evident from Table 3 a significant effect on adult worms (50%; $P < 0.001$) was shown by compound **18** at 100mg/kg. In terms of embryostatic activity, it exerted significant ($P < 0.01$) efficacy by sterilizing about 68% of the surviving female worms compared to 20% observed in the untreated controls. The efficacy of the compound was found to be lower at 50 mg/kg as compared to 100mg/kg. Compound **15** at 100mg/kg marginally (20%) exerted macrofilaricidal effect. On the other hand, compounds **10** and **15** at 100mg/kg, affected the female reproductive potentials to the tune of only 35 and 26% respectively. None of the compounds affected circulating mf. The control drug, DEC at a dose of 25 mg /kg (i.p.) caused more than 65% reduction in microfilaraemia and around 30% female sterilizing action. Untreated control animals showed progressive rise in microfilaraemia till termination of the experiment. About 20% of live female worms recovered from these animals were sterile.

Please insert Table 3

As compound **18** with 4- fluorophenyl and *n*-pentyl substituents was found to be the most potent antifilarial in the above two experiments we were prompted to see its effect on the adulticidal activity against filarial worms in *B. malayi*-jird model. It is evident from the results (Table 4) the standard antifilarial drug DEC (12.5mg/kg, the effective dose of the drug against animal filariid, *Litomosoides carinii*), did not show any noticeable microfilaricidal activity and about 10% adulticidal activity was observed only as compared to untreated controls. However the synthetic compound **18** displayed about 46% adulticidal activity and 34% of the sterilized female worms were recovered. Untreated control animals showed no effect on *mf* of peritoneal cavity of any of the animals. About 16% of live female worms recovered from these animals were sterile. The results indicate that compound **18** may serve as lead molecule for further optimization and development of novel class of antifilarial agents.

Please insert Table 4

In conclusion we have developed and efficient synthesis of a series of 4-aryl-2-sulfanyl-6-methyl-1,4- dihydropyridines by simple alkylation of dihydropyrimidine thiones with alkyl halides. One of the compounds displayed potent activity in vitro and in vivo it exerted adulticidal activity alongwith female worms sterilization. Compound **18**, found active may serve as a proptotype lead for further optimization and development of new antifilarial agents.

3. Experimental:

3.1 General methods

Commercially available reagent grade chemicals were used as received. All reactions were followed by TLC on Merck Kieselgel 60 F₂₅₄, with detection by UV light and/or spraying 20% KMnO₄ aqueous solution. Column chromatography was performed on silica gel (230–400 mesh, Merck). IR spectra were recorded as thin films or neat chloroform solution with a Perkin-Elmer Spectrum RX-1 (4000-450 cm⁻¹) spectrophotometer. The ¹H and ¹³C NMR spectra were recorded on a Bruker DRX -300 in (*D*) chloroform, chemical shift values in ppm relative to SiMe₄ as internal reference, unless otherwise stated; signals are reported as s (singlet), d (doublet), t (triplet), m (multiplet); *J* in Hz. Fast atom bombardment mass spectra (FABMS) were performed by the Mass Spectrometer Jeol SX-102(FAB). Elemental analyses were performed on a Perkin-Elmer 2400 II elemental analyzer.

3.2. Typical experimental procedure for compound 8-21: To a magnetically stirred solution of compounds **2-7** (1 mmol) in acetone, K₂CO₃ (1 mmol) was added and reaction mixture was stirred for 10 minutes. After that alkyl bromide (1mmol) and tetra butyl ammonium bromide (20 mol%) was added and reaction mixture was stirred for desired time at room temperature. After completion reaction mixture was evaporated and crude mass was extracted by ethyl acetate and water. Organic layer was dried (anhyd. Na₂SO₄) and evaporated under reduced pressure to get the crude mass which was column chromatographed over silica gel (60-120 mesh) using hexane-EtOAc as eluent to give the compounds 8-21.

3.2.1. 2-Benzylsulfanyl-6-methyl-4-naphthalen-1-yl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(8): It was obtained by the reaction **2** (1.1g, 3.37 mmol), K₂CO₃ (0.47g, 3.37 mmol) and benzyl bromide (0.4 mL, 3.37 mmol) as a white Solid (0.98g, 70%); m.p. 132-133 °C; ¹H NMR (200 MHz, CDCl₃): δ 0.99 (t, 3H, *J* = 7.0 Hz), 2.42 (s, 3H), 3.87-4.16 (m, 4H), 6.57 (s, 1H), 6.83-7.05 (m, 4H), 7.33-7.58 (m, 5H), 7.74-7.89 (m, 2H), 8.74 (d, 1H, *J* = 8.2 Hz); ¹³C NMR (50 MHz, CDCl₃): δ 14.5, 19.0, 35.6, 56.6, 60.0, 99.6, 124.1, 125.8, 126.3, 127.4, 128.2, 128.8, 129.1, 131.6, 134.5, 138.2, 139.6, 167.0; IR (KBr) cm⁻¹: 3283, 2362, 1650, 1593; MS (FAB): *m/z* 417 (M+H)⁺; Anal. Calcd for C₂₅H₂₄N₂O₂S C, 72.09; H, 5.81; N, 6.73; Found C, 71.98; H, 5.94; N, 6.86.

3.2.2. 6-Methyl-4-naphthalen-1-yl-2-pentylsulfanyl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(9): It was obtained by the reaction **2** (0.8g, 2.45 mmol), K₂CO₃ (0.38g, 2.45 mmol) and pentyl bromide (0.31 mL, 2.45 mmol) as a white Solid (0.7g, 72%); m.p. 92-94 °C; ¹H NMR (200 MHz, CDCl₃): δ 0.70 (t, 3H, *J* = 6.7 Hz), 0.86-1.05 (m, 7H), 1.19-1.25 (m, 2H), 2.46 (s, 3H), 2.51-2.87 (m, 2H), 4.01 (q, 2H, *J* = 7.0 Hz), 6.51 (s, 1H), 7.23-7.54 (m, 4H), 7.69-7.84 (m, 2H), 8.70 (d, 1H, *J* = 8.2 Hz); ¹³C NMR (50 MHz, CDCl₃): δ 14.2, 14.5, 19.1, 22.4, 29.7, 31.2, 31.6, 57.0, 60.0, 102.0, 123.8, 125.7, 126.1, 128.1, 128.7, 131.6, 134.5, 139.3, 167.1; IR (KBr) cm⁻¹: 3303, 2362, 1654; MS (FAB): m/z 397 (M+H)⁺; Anal. Calcd for C₂₃H₂₈N₂O₂S C, 69.66; H, 7.12; N, 7.06; Found C, 69.77; H, 7.24; N, 6.96.

3.2.3. 2-Butylsulfanyl-6-methyl-4-naphthalen-1-yl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(10): It was obtained by the reaction **2** (1g, 3.06 mmol), K₂CO₃ (0.42g, 3.06 mmol) and butyl bromide (0.33 mL, 3.06 mmol) as a white Solid (0.93g, 80%); m.p. 97-98 °C; ¹H NMR (200 MHz, CDCl₃): δ 0.57 (t, 3H, *J* = 6.9 Hz), 0.84-1.25 (m, 7H), 2.46 (s, 3H), 2.64-2.86 (m, 2H), 4.01 (q, 2H, *J* = 7.0 Hz), 6.51 (s, 1H), 7.23-7.84 (m, 7H), 8.74 (d, 1H, *J* = 8.1 Hz); ¹³C NMR (50 MHz, CDCl₃): δ 13.8, 14.5, 19.4, 22.2, 31.3, 32.0, 56.1, 60.0, 123.9, 125.7, 126.1, 128.1, 128.7, 131.7, 134.5, 139.3, 167.1; IR (KBr) cm⁻¹: 3289, 2363, 1653; MS (FAB): m/z 383 (M+H)⁺; Anal. Calcd for C₂₂H₂₆N₂O₂S C, 69.08; H, 6.85; N, 7.32; Found C, 69.13; H, 6.79; N, 7.39.

3.2.4. 6-Methyl-4-naphthalen-1-yl-2-tetradecylsulfanyl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(11): It was obtained by the reaction **2** (1.3g, 3.98 mmol), K₂CO₃ (0.55g, 3.98 mmol) and tetradecyl bromide (1 mL, 3.98 mmol) as a white Solid (1.35g, 65%); m.p. 86-87 °C; ¹H NMR (200 MHz, CDCl₃): δ 0.85-1.26 (m, 30H), 2.46 (s, 3H), 2.52-2.98 (m, 2H), 3.99 (q, 2H, *J* = 7.0 Hz), 6.16 (s, 1H), 6.51 (s, 1H), 7.23-7.55 (m, 4H), 7.69-7.84 (m, 2H), 8.70 (d, 1H, *J* = 8.2 Hz); ¹³C NMR (50 MHz, CDCl₃): δ 14.5, 19.0, 23.1, 29.1, 29.4, 29.8, 30.1, 31.8, 32.3,

56.6, 60.1, 99.5, 123.5, 125.7, 125.9, 126.0, 127.0, 128.0, 128.6, 129.5, 131.9, 134.5, 139.2, 146.0, 149.4, 167.3; IR (KBr) cm^{-1} : 3302, 2363, 1650, 1597; MS (FAB): m/z 523 ($\text{M}+\text{H}^+$); Anal. Calcd for $\text{C}_{32}\text{H}_{46}\text{N}_2\text{O}_2\text{S}$ C, 73.52; H, 8.87; N, 5.36; Found C, 73.68; H, 9.05; N, 5.51.

3.2.4. 2-Benzylsulfanyl-6-methyl-4-(3-nitro-phenyl)-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(12): It was obtained by the reaction **3** (1.0g, 3.11 mmol), K_2CO_3 (0.43g, 3.11 mmol) and benzyl bromide (0.37 mL, 3.11 mmol) as a greenish Solid (0.76g, 60%); m.p. 122-124 °C; ^1H NMR (200 MHz, CDCl_3): δ 1.21 (t, 3H, $J = 7.1$ Hz), 2.31 (s, 3H), 4.06-4.16 (m, 3H), 4.28 (d, 1H, $J = 13.6$ Hz), 5.82 (s, 1H), 6.37 (s, 1H), 7.14-7.22 (m, 5H), 7.41 (t, 1H, $J = 7.8$ Hz), 7.59 (d, 1H, $J = 7.6$ Hz), 8.06-8.11 (m, 2H); ^{13}C NMR (50 MHz, CDCl_3): δ 14.6, 19.1, 35.5, 59.8, 60.5, 100.3, 122.4, 122.5, 127.7, 128.8, 129.0, 129.2, 129.5, 133.9, 137.5, 137.5, 145.6, 147.2, 148.7, 150.4, 166.7; IR (KBr) cm^{-1} : 3326, 2364, 1678, 1653; MS (FAB): m/z 411 ($\text{M}+\text{H}^+$); Anal. Calcd for $\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_4\text{S}$ C, 61.30; H, 5.14; N, 10.21; Found C, 61.41; H, 5.27; N, 10.10.

3.2.5. 6-Methyl-4-(3-nitro-phenyl)-2-pentylsulfanyl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(13): It was obtained by the reaction **3** (1.0g, 3.11 mmol), K_2CO_3 (0.43g, 3.11 mmol) and pentyl bromide (0.39 mL, 3.11 mmol) as a white Solid (0.91g, 75%); m.p. 119-120 °C; ^1H NMR (200 MHz, CDCl_3): δ 0.82 (t, 3H, $J = 7.1$ Hz), 1.16-1.32 (m, 7H), 1.53-1.63 (m, 2H), 2.34 (s, 3H), 2.89-3.04 (m, 2H), 4.11 (q, 2H, $J = 7.0$ Hz), 5.80 (s, 1H), 6.35 (s, 1H), 7.45 (t, 1H, $J = 7.8$ Hz), 7.65 (d, 1H, $J = 7.8$ Hz), 8.05-8.16 (m, 2H); ^{13}C NMR (50 MHz, CDCl_3): δ 14.2, 14.6, 19.2, 22.5, 29.4, 31.1, 31.4, 59.5, 60.5, 100.1, 122.4, 129.5, 133.8, 145.7, 147.3, 148.6, 151.2, 166.8; IR (KBr) cm^{-1} : 3432, 2364, 1699, 1640; MS (FAB): m/z 392 ($\text{M}+\text{H}^+$); Anal. Calcd for $\text{C}_{19}\text{H}_{25}\text{N}_3\text{O}_4\text{S}$ C, 58.29; H, 6.44; N, 10.73; Found C, 58.14; H, 6.57; N, 10.61.

3.2.6. 2-Butylsulfanyl-6-methyl-4-(3-nitro-phenyl)-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(14): It was obtained by the reaction **3** (0.9g, 2.80 mmol), K_2CO_3 (0.39g, 2.80 mmol) and butyl bromide (0.31 mL, 2.80 mmol) as a white Solid (0.74g, 70%); m.p. 98-99 °C; ^1H NMR (200 MHz, CDCl_3): δ 0.84 (t, 3H, $J = 7.0$ Hz), 1.22 (t, 3H, $J = 7.1$ Hz), 1.27-1.39 (m, 2H), 1.52-1.68 (m, 2H), 2.35 (s, 3H), 2.91-

3.08 (m, 2H), 4.07 (q, 2H, $J = 7.1$ Hz), 5.81 (s, 1H), 6.36 (s, 1H), 7.45 (t, 1H, $J = 7.8$ Hz), 7.66 (d, 1H, $J = 7.7$ Hz), 8.07-8.16 (m, 2H); ^{13}C NMR (50 MHz, CDCl_3): δ 13.9, 14.6, 19.1, 22.1, 31.1, 31.8, 59.4, 60.5, 122.4, 129.6, 133.7, 147.2, 148.6, 166.9; IR (KBr) cm^{-1} : 3391, 1700, 1637; MS (FAB): m/z 377 (M+H) $^+$; Anal. Calcd for $\text{C}_{18}\text{H}_{23}\text{N}_3\text{O}_4\text{S}$ C, 57.28; H, 6.14; N, 11.13; Found C, 57.16; H, 6.28; N, 11.24.

3.2.7. 2-Benzylsulfanyl-4-(4-methoxy-phenyl)-6-methyl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(15): It was obtained by the reaction **4** (1.5g, 4.90 mmol), K_2CO_3 (0.67g, 4.90 mmol) and benzyl bromide (0.58 mL, 4.90 mmol) as colorless oil (1.26g, 65%); ^1H NMR (200 MHz, CDCl_3): δ 1.19 (t, 3H, $J = 7.0$ Hz), 2.33 (s, 3H), 3.79 (s, 3H), 4.05-4.46 (m, 4H), 5.69 (s, 1H), 6.79-6.32 (m, 9H); ^{13}C NMR (50 MHz, CDCl_3): δ 14.6, 19.6, 35.2, 55.6, 58.6, 60.2, 102.9, 114.1, 127.7, 128.5, 128.9, 129.4, 130.5, 137.5, 137.9, 159.2, 167.3; IR (neat) cm^{-1} : 3362, 2363, 1690, 1598; MS (FAB): m/z 397 (M+H) $^+$; Anal. Calcd for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_3\text{S}$ C, 66.64; H, 6.10; N, 7.07; Found C, 66.76; H 6.22; N, 7.14.

3.2.8. 4-(4-Methoxy-phenyl)-6-methyl-2-pentylsulfanyl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(16): It was obtained by the reaction **4** (1.3g, 4.24 mmol), K_2CO_3 (0.59g, 4.24 mmol) and pentyl bromide (0.53 mL, 4.24 mmol) as an oil (0.82g, 78%); ^1H NMR (200 MHz, CDCl_3): δ 0.85 (t, 3H, $J = 6.7$ Hz), 1.16-1.30 (m, 3H), 1.53-1.60 (m, 2H), 2.26 (s, 3H), 2.88-2.94 (m, 2H), 3.77 (s, 3H), 5.54 (s, 1H), 6.73-6.83 (m, 2H), 7.14-7.21 (m, 2H); ^{13}C NMR (50 MHz, CDCl_3): δ 14.3, 14.7, 20.6, 22.5, 29.5, 31.2, 55.4, 57.8, 60.0, 102.0, 114.0, 128.3, 130.4, 137.6, 159.1, 167.1 ; IR (KBr) cm^{-1} : 3298, 1680, 1653; MS (FAB): m/z 377 (M+H) $^+$; Anal. Calcd for $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_3\text{S}$ C, 63.80; H, 7.50; N, 7.44; Found C, 63.67; H 7.40; N, 7.56.

3.2.9. 4-(4-Methoxy-phenyl)-6-methyl-2-tetradecylsulfanyl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(17): It was obtained by the reaction **4** (1.5g, 4.90 mmol), K_2CO_3 (0.67g, 4.90 mmol) and tetradecyl bromide (1.34 mL, 4.90 mmol) as a semi Solid (1.97g, 80%); ^1H NMR (200 MHz, CDCl_3): δ 0.88 (t, 3H, $J = 6.6$ Hz), 1.16-1.25 (m, 21H), 1.42-1.60 (m, 2H), 2.30 (s, 3H), 2.69-3.18 (m, 2H), 3.77 (s, 3H), 4.08 (q, 2H, $J = 7.0$ Hz), 5.66 (s, 1H), 6.10 (s, 1H), 6.79 (d, 2H, $J = 8.6$ Hz), 7.22 (d, 2H, $J = 8.7$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 14.5, 14.7, 23.1,

29.1, 29.5, 29.7, 29.9, 30.1, 31.3, 32.3, 55.4, 56.0, 60.0, 114.0, 114.6, 128.3, 132.3, 137.6, 159.1, 167.1; MS (FAB): m/z 503 (M+H)⁺; Anal. Calcd for C₂₉H₄₆N₂O₃S C, 69.28; H, 9.22; N, 5.57; Found C, 69.40; H 9.30; N, 5.49.

3.2.10. 4-(4-Fluoro-phenyl)-6-methyl-2-pentylsulfanyl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(18): It was obtained by the reaction **5** (1.5g, 5.10 mmol), K₂CO₃ (0.70g, 5.10 mmol) and pentyl bromide (0.63 mL, 5.10 mmol) as an oil (1.3g, 70%); ¹H NMR (200 MHz, CDCl₃): δ 0.94 (t, 3H, *J* = 6.6 Hz), 1.23-1.38 (m, 7H), 1.58-1.62 (m, 2H), 2.33 (s, 3H), 2.89-2.96 (m, 2H), 4.11 (q, 2H, *J* = 7.0 Hz), 5.72 (s, 1H), 6.96-7.05 (m, 2H), 7.30-7.36 (m, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 14.3, 14.6, 20.3, 22.5, 29.5, 31.2, 31.3, 58.0, 60.1, 102.3, 115.2, 115.6, 116.1, 128.8, 128.9, 140.9, 159.9, 164.8, 166.9; IR (neat) cm⁻¹: 3293, 2365, 1653; MS (FAB): m/z 365 (M+H)⁺; Anal. Calcd for C₁₉H₂₅FN₂O₂S C, 62.61; H, 6.91; N, 7.69; Found C, 62.66; H 6.99; N, 7.57.

3.2.11. 4-(4-Fluoro-phenyl)-6-methyl-2-tetradecylsulfanyl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(19): It was obtained by the reaction **5** (1.5g, 5.10 mmol), K₂CO₃ (0.70g, 5.10 mmol) and tetradecyl bromide (1.39 mL, 5.10 mmol) as a light green solid (2.1g, 85%); m.p. 50-51 °C; ¹H NMR (200 MHz, CDCl₃): δ 0.88 (t, 3H, *J* = 6.7 Hz), 1.16-1.25 (m, 25H), 1.54-1.62 (m, 2H), 2.31 (s, 3H), 2.84-3.07 (m, 2H), 4.07 (q, 2H, *J* = 7.0 Hz), 5.65 (s, 1H), 6.17 (s, 1H), 6.90-6.98 (m, 2H), 7.23-7.29 (m, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 14.5, 14.6, 19.0, 23.1, 29.1, 29.5, 29.7, 29.8, 30.0, 31.4, 32.3, 59.2, 60.2, 101.2, 115.2, 115.6, 128.8, 128.9, 141.0, 159.9, 164.7, 167.2; IR (neat) cm⁻¹: 3310, 1652, 1601; MS (FAB): m/z 491 (M+H)⁺; Anal. Calcd for C₂₈H₄₃FN₂O₂S C, 68.53; H, 8.83; N, 5.71; Found C, 68.65; H 8.95; N, 5.78.

3.2.12. 4-(4-Chloro-phenyl)-6-methyl-2-pentylsulfanyl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(20): It was obtained by the reaction **6** (1.6g, 5.16 mmol), K₂CO₃ (0.71g, 5.16 mmol) and pentyl bromide (0.64 mL, 5.16 mmol) as an oil (1.37g, 70%); ¹H NMR (200 MHz,

CDCl₃): δ 0.86 (t, 3H, J = 6.6 Hz), 1.10-1.33 (m, 7H), 1.53-1.60 (m, 2H), 2.32 (s, 3H), 2.89-3.03 (m, 2H), 4.04 (q, 2H, J = 7.0 Hz), 5.58 (s, 1H), 7.12-7.33 (m, 4H); ¹³C NMR (50 MHz, CDCl₃): δ 14.2, 14.6, 19.1, 22.5, 23.0, 29.3, 29.4, 31.1, 31.4, 58.2, 60.5, 101.5, 128.4, 128.7, 129.0, 129.2, 133.2, 143.5, 167.0 ; IR (neat) cm⁻¹: 3295, 2362, 1652; MS (FAB): m/z 381 (M+H)⁺; Anal. Calcd for C₁₉H₂₅ClN₂O₂S C, 59.91; H, 6.61; N, 7.35; Found C, 60.07; H 6.78; N, 7.51.

3.2.13. 2-Benzylsulfanyl-6-methyl-4-thiophen-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester(21): It was obtained by the reaction **7** (0.8g, 2.83 mmol), K₂CO₃ (0.39g, 2.83 mmol) and benzyl bromide (0.34 mL, 2.83 mmol) as a white solid (0.68g, 65%); Solid, m.p. 89-90 °C; ¹H NMR (200 MHz, CDCl₃): δ 0.125 (t, 3H, J = 7.0 Hz), 2.30 (s, 3H), 4.12-4.26 (m, 3H), 4.37 (d, 1H, J = 13.3 Hz), 5.97 (s, 1H), 6.87-7.28 (m, 8H); ¹³C NMR (50 MHz, CDCl₃): δ 14.7, 18.9, 35.8, 55.3, 60.4, 101.5, 123.9, 124.4, 126.8, 127.7, 128.9, 129.4, 137.7, 145.5, 149.2, 151.7, 167.0; IR (KBr) cm⁻¹: 3297, 2358, 1647; MS (ESI): m/z 373.1 (M+H)⁺.

Acknowledgements: This paper bears CDRI Communication No. **7347**. Authors thank SAIF Division for spectroscopic data. BKS and Nisha

Thank CSIR for SRF. Financial assistance from ICMR project is gratefully acknowledged.

References:

- [1] P. Fischer, P. Manoempil, T. Supali, G. Servais*, *P. Rücker* *Tran R Soc Trop Med H.* 11 (2006) 464-469
- [2] T.J.Z. Galvez, *Filaria Journal* 2 (2003) 1 and references cited therein
- [3] P. A. Thomas, *Parasitology* 122 (2001) S65.
- [4] D. Molyneux, *Filaria Journal* 2 (2003) 2.
- [5] E.A.. Ottesen, *Trop. Med. Int. Health*, 5 (2000) 591
- [6] E.A. Ottesen, *Am. J. Trop. Med. Hyg.* 41 (1989) S9.
- [7] E. Michael, D. A.P. Bundy, *Parasitol. Today* 13 (1997) 472.

- [8] A.M. Khan, Mahanta J. *Curr. Sci.* 88 (2005) 1718.
- [9] P.K. Das, S. P. Pani, *Int. Med. Sci. Acad.* 13 (2000) 18.
- [10] A.. Hoerauf, L. Volkmann, C. Hamelmann, O. Adjei, I.B. Autenrieth, B. Fleischer, D.W. Buttner, *Lancet* 35 (2000) 1242.
- [11] R.P. Tripathi, D. Katiyar, N. Dwivedi, B.K. Singh, J. Pandey, *Current Medicinal Chemistry* 13 (2006).
- [12] L. Collier, A.. Balows, M. Sussman, *Parasitol.* 5 (1998) 349.
- [13] C. Bose, S.K. Agarwal, R.K. Chatterjee, V.M. Srivastava, P.M. Chauhan, R.K. Chatterjee, *Indian J. Chem.* 33B (1994) 32.
- [14] S. Srivastava, P.M. Chauhan, A.P. Bhaduri, P.K. Murthy, R.K. Chatterjee, *Bioorg. Med. Chem. Lett.* 10 (2000) 313.
- [15] J.M. Matthews, F. Liotta, W. Hageman, R.A. Rivero, L. Westover, M. Yang, J. Xu, K. Demarest, *Bioorganic Med. Chem. Lett.* 14 (2004) 1155.
- [16] K.S. Atwal, G.C. Rovnyak, S.D. Kimball, D.M. Floyd, S. Moreland, B.N. Swanson, J.Z. Gougoutas, J. Schwartz, K.M. Smillie, M.F. Malley, *J. Med. Chem.* 33 (1990) 2629.
- [17] C.O. Kappe, *Molecules* 3 (1998) 1.
- [18] E. Tramontano, M.E. Marongiu, A. De Montis, A.G. Loi, M. Artico, S. Massa, A. Mai, P. La Colla, *Microbiologica* 17 (1994) 269.
- [19] A. Mai, M. Artico, G. Sbardella, S. Massa, A.G. Loi, E. Tramontano, P. Scano, P.J. La Colla, *Med.Chem.* 38 (1995) 3258.
- [20] L. Ji, Fen-E. Chen, E. D. Clercq, J. Balzarini, C. Pannecouque, *J. Med. Chem.* 50 (2007) 1778.
- [21] R.C. Mishra, N.Tewari, K. Arora, R. Ahmad, R.P. Tripathi, V.K. Tiwari, R.D. Walter, A.K. Srivatava, *Combi Chem & Highthroughput Screening* 6 (2003) 37.
- [22] N. Dwivedi, R.C. Mishra, R.P. Tripathi, *Lett. Org. Chem.* 2 (2005) 450-457.
- [23] P.K. Murthy, R.K. Chatterjee, *Curr. Sci.* 77 (1999) 1084.
- [24] G. Lammler, E. Wolf, *Tropenmed. und Parasitol.* 28 (1977) 205.
- [25] R.K. Chatterjee, Nigar Fatma, P.K. Murthy, P. Sinha, D.K. Kulshrestha, B.N. Dhawan, *Drug. Dev. Res.* 26 (1992) 67.
- [26] R.L. Gaur, S. Dixit, M.K. Sahoo, M. Khanna, S. Singh, P.K. Murthy, *Parasitology* 2 (2006) 1-8.

Supplementary data and full experimental details along with the physical data and X-ray are enclosed as separate file.